Guillain-Barre syndrome
What it is
Guillain-Barre syndrome is an acute immune-mediated polyneuropathy, written out as acute inflammatory demyelinating polyradiculoneuropathy, that typically manifests with bilateral ascending flaccid paralysis and sensory involvement such as paresthesia. Said another way, it is an acute, rapidly progressive demyelinating autoimmune disorder of the peripheral nerves that results in weakness. It is the most common polyneuropathy. Adults are affected more frequently than children.
The pathogenesis is a chain that is worth holding whole, because it explains both the delay and the treatment. An infection, typically Campylobacter jejuni, is taken up by an antigen-presenting cell, which acts on a B cell and then on a plasma cell, which makes cross-reactive antibody by molecular mimicry; the antibody, aimed at the organism, lands on the patient's own nerve instead. The antigens named are those in the myelin sheath, other Schwann-cell antigens, and axon membranes, and the result is immune-mediated segmental demyelination of the neuron of a peripheral or cranial nerve. Put shorter, the antibody attacks myelin.
The preceding infection
It is post-infectious. Approximately 65% of patients have an upper respiratory tract or gastrointestinal infection before the onset of symptoms, and the onset is within 2-4 weeks of that illness or of an immunization.
The organisms named are Campylobacter jejuni, cytomegalovirus, Epstein-Barr virus and Mycoplasma pneumoniae, and the association is also given with influenza infection, viral infection or influenza vaccination. Campylobacter is the one to name: in the table of diarrheal pathogens its unique clinical clue is poultry and Guillain-Barre syndrome risk, and it is comma-shaped on stool culture. Asked which complication belongs to which dysentery, Guillain-Barre syndrome goes with C. jejuni while hemolytic uremic syndrome goes with EHEC, mesenteric adenitis with Yersinia or viral causes, and reactive arthritis with Salmonella and Shigella.
AIDP, the acute variant and the predominant subtype affecting 60-80% of GBS patients in North America and Europe, is the one associated with Campylobacter and CMV.